spacer
Collapse Statistics
241 human active and 13 inactive phosphatases in total;
194 phosphatases have substrate data;
--------------------------------
336 protein substrates;
83 non-protein substrates;
1215 dephosphorylation interactions;
--------------------------------
299 KEGG pathways;
876 Reactome pathways;
--------------------------------
last scientific update:
11 Mar, 2019
last maintenance update:
01 Sep, 2023

spacer

CHEBI:17622

Name dUMPC00365
Download: mol | sdf
Synonyms02'-deoxyuridine 5'-monophosphate;
2'-deoxyuridine 5'-phosphate;
2'-deoxy-5'-o-phosphonatouridine;
5'-dump;
Deoxyuridine 5'-phosphate;
Deoxyuridine monophosphate;
Deoxyuridylate;
Deoxyuridylic acid;
Dump;
Definition A pyrimidine 2'-deoxyribonucleoside 5'-monophosphate having uracil as the nucleobase.
Molecular Weight
(Exact mass)
308.1819 (308.041)
Molecular Formula C9H13N2O8P
SMILES O[C@H]1C[C@@H](O[C@@H]1COP(O)(O)=O)n1ccc(=O)[nH]c1=O
InChI InChI=1S/C9H13N2O8P/c12-5-3-8(11-2-1-7(13)10-9(11)14)19-6(5)4-18-20(15,16)17/h1-2,5-6,8,12H,3-4H2,(H,10,13,14)(H2,15,16,17)/t5-,6+,8+/m0/s1
InChI Key JSRLJPSBLDHEIO-SHYZEUOFSA-N
Crosslinking annotations KEGG:C00365 | 3DMET:B01231 | CAS:964-26-1 | ChEBI:17622 | ChEMBL:CHEMBL211312 | KNApSAcK:C00019282 | NIKKAJI:J298.569A | PDB-CCD:DU | PDB-CCD:UMP | PubChem:3656 |

Pathway ID Pathway Name Pathway Description (KEGG)
map00240Pyrimidine metabolismNA
map01100Metabolic pathwaysNA
map01523Antifolate resistanceSince the 1940s, antifolates have played a pivotal role in drug treatment of malignant, microbial, parasitic and chronic inflammatory diseases. The molecular basis of the anti-proliferative activity of antifolates relies on inhibition of key enzymes in folate metabolism, which results in disruption of purine and thymidylate biosynthesis, inhibition of DNA replication and cell death. The anti-inflammatory properties of antifolate have been most strongly related to its ability to block the release of pro-inflammatory cytokines such as tumour necrosis factor (TNF)-alpha or interleukin (IL)-1beta. Cells may develop resistance to an antifolate drug by virtue of impaired drug transport into cells, augmented drug export, impaired activation of antifolates through polyglutamylation, augmented hydrolysis of antifolate polyglutamates, increased expression and mutation of target enzymes, and the augmentation of cellular tetrahydrofolate-cofactor pools in cells.